The effect of urinary protein excretion in post-renal transplant recurrent nephrotic syndrome on basiliximab pharmacokinetics and pharmacodynamics in a pediatric patient

Transplantation Proceedings

Volumn 37, Issue 2, 2005, Pages 879-880

  Nagai, T ^a,b   Goto, Y ^a   Haba, T ^a   Uchida, K ^a  

^a NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^b NONE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB;

ANTIGEN EXPRESSION; CLINICAL TRIAL; CONFERENCE PAPER; GLOMERULOSCLEROSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PROTEIN URINE LEVEL; T LYMPHOCYTE;

EID: 17844375155     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2005.02.029     Document Type: Conference Paper

References (4)

1. L. Pape Single center experience with basiliximab in paediatric renal transplantation Nephrol Dial Transplant 17 2002 276
2. G. Offner A multicenter, open-label, pharmacokinetic/pharmacodynamic safety, and tolerability study of Basiliximab (SIMULECT) in pediatric de novo renal transplant recipient Transplantation 74 2002 961
3. Kovarik J: A rational dosing algorithm for Basiliximab (SIMULECT) in pediatric transplantation based on pharmacokinetic-dynamic evaluations. Transplantation 74:966, 2002
4. R. Salmon Intravenous cyclosporine therapy in recurrent nephrotic syndrome after renal transplantation in children Transplantation 75 2003 810